A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors.

The article discusses a clinical trial, NCT06804824, conducted by Vividion Therapeutics, Inc., to evaluate the safety, tolerability, and anti-tumor activity of VVD-159642, a RAS-PI3Ka inhibitor, in participants with advanced solid tumors. The study aims to assess the pharmacokinetics, pharmacodynamics, and preliminary efficacy of VVD-159642 as a single agent and in combination with sotorasib or trametinib. The trial is set to begin on March 1, 2025, with a primary completion date of August 1, 2027, and aims to enroll 220 participants with specific inclusion and exclusion criteria related to solid tumors and other health conditions. [Extracted from the article]